PMID- 38335182
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240214
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 19
IP  - 2
DP  - 2024
TI  - Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of 
      cicatricial alopecia: A systematic review.
PG  - e0293433
LID - 10.1371/journal.pone.0293433 [doi]
LID - e0293433
AB  - BACKGROUND: Cicatricial alopecia (CA) refers to various conditions that result in 
      permanent hair loss. Treatment of CA has always been challenging. Regarding 
      immune-mediated pathophysiology for many CA subtypes, the administration of Janus 
      kinase (JAK) and tumor necrosis factor (TNF) inhibitors have potentiated the 
      treatments of CA. METHODS: After a thorough systematic search in PubMed/Medline, 
      Embase, Web of Science, Scopus, Google Scholar, ClinicalTrials.gov, and WHO 
      ICTRP, a total of 3,532 relevant records were retrieved and screened. 
      Accordingly, 56 studies met the eligibility criteria and entered the review. 
      RESULTS: Among JAK inhibitors, oral tofacitinib was the most frequently reported 
      and the most effective treatment in improving signs and symptoms of CA with 
      minimal adverse effects (AEs). Baricitinib was another JAK inhibitor with 
      sustained improvement while causing mild AEs. As a TNF inhibitor, adalimumab 
      induced a rapid and stable improvement in signs and symptoms in most patients 
      with rare, tolerable AEs. Thalidomide was the other frequently reported yet 
      controversial TNF inhibitor, which caused a rapid and significant improvement in 
      the condition. However, it may result in mild to severe AEs, particularly 
      neuropathies. Infliximab is a TNF inhibitor with mostly favorable results, albeit 
      in a few patients caused treatable dermatological AEs. Apremilast and 
      certolizumab pegol caused an incomplete amelioration of signs and symptoms with 
      no AEs. Lenalidomide is another TNF inhibitor that can induce temporary 
      improvement in CA with probable AEs. It is noteworthy that utilizing adalimumab, 
      infliximab, etanercept, golimumab, and an anonymous TNF inhibitor has induced 
      paradoxical CA and other A.E.s in some patients. CONCLUSION: Recent studies have 
      recommended JAK and TNF inhibitors, especially oral tofacitinib and adalimumab, 
      as a new modality or adjuvant therapy to previous medications for primary CA. 
      Nonetheless, monitoring AEs on a regular basis is suggested, and further 
      extensive studies are required before definitive recommendations.
CI  - Copyright: (c) 2024 Hajizadeh et al. This is an open access article distributed 
      under the terms of the Creative Commons Attribution License, which permits 
      unrestricted use, distribution, and reproduction in any medium, provided the 
      original author and source are credited.
FAU - Hajizadeh, Nima
AU  - Hajizadeh N
AUID- ORCID: 0000-0001-6323-9252
AD  - School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
AD  - Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran 
      University of Medical Sciences, Tehran, Iran.
FAU - Heidari, Amirhossein
AU  - Heidari A
AD  - Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, 
      Iran.
FAU - Sadeghi, Sara
AU  - Sadeghi S
AD  - Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran 
      University of Medical Sciences, Tehran, Iran.
AD  - Department of Medicine, New York Health System, South Brooklyn Hospital, New 
      York, NY, United States of America.
FAU - Goodarzi, Azadeh
AU  - Goodarzi A
AUID- ORCID: 0000-0002-1249-4429
AD  - Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran 
      University of Medical Sciences, Tehran, Iran.
AD  - Department of Dermatology, Faculty of Dermatology, Rasool Akram Medical Complex 
      Clinical Research Development Center (RCRDC), School of Medicine, Iran University 
      of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20240209
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - FYS6T7F842 (Adalimumab)
RN  - 0 (Janus Kinase Inhibitors)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - B72HH48FLU (Infliximab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Humans
MH  - Adalimumab/therapeutic use
MH  - *Janus Kinase Inhibitors/adverse effects
MH  - Tumor Necrosis Factor Inhibitors
MH  - Infliximab
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Alopecia/drug therapy
MH  - Tumor Necrosis Factor-alpha
PMC - PMC10857607
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/02/09 18:42
MHDA- 2024/02/10 14:46
PMCR- 2024/02/09
CRDT- 2024/02/09 13:34
PHST- 2023/07/07 00:00 [received]
PHST- 2023/10/12 00:00 [accepted]
PHST- 2024/02/10 14:46 [medline]
PHST- 2024/02/09 18:42 [pubmed]
PHST- 2024/02/09 13:34 [entrez]
PHST- 2024/02/09 00:00 [pmc-release]
AID - PONE-D-23-21106 [pii]
AID - 10.1371/journal.pone.0293433 [doi]
PST - epublish
SO  - PLoS One. 2024 Feb 9;19(2):e0293433. doi: 10.1371/journal.pone.0293433. 
      eCollection 2024.